Intra-articular rheumatoid nodules and triggering of the knee joint

Z Tak-Diamant, F J J Hooning van Duyvenbode, F Eulderink, M Janssen

Abstract
Rheumatoid nodules are a common extra-articular manifestation in rheumatoid arthritis. Intra-articular localisation of these nodules is rare and may produce clinical symptoms. Seven patients with walking problems due to an intra-articular rheumatoid nodule, which became entrapped on the ridge of the tibial plateau of the knee joint resulting in a phenomenon referred to as trigger knee, are described. After excision of the nodules all symptoms completely disappeared.

Rheumatoid nodules are characteristic extra-articular manifestations of rheumatoid arthritis. They are mainly found in the presence of rheumatoid factor and may be indicative of more severe disease. These nodules occur in 20–35% of patients with rheumatoid arthritis and they are commonly found subcutaneously over pressure points—for example, at the elbows, the buttocks, and the scalp. They can also develop in several internal organs, such as the lungs, kidneys, and heart. Intra-articular rheumatoid nodules, however, are rare. In this retrospective study we considered seven patients with walking problems associated with intra-articular rheumatoid nodules of the knee joint.

Patients and methods
From 1972 to 1989 six patients who visited our outpatient rheumatology clinic had seropositive rheumatoid arthritis and symptoms typical of intra-articular rheumatoid nodules of the knee joint. We also performed a computer search for patients who had had an operation for triggering of the knee joint caused by rheumatoid nodules and another patient was identified. We retrospectively studied the clinical features associated with the presence of intra-articular rheumatoid nodules in these seven patients.

Clinical data were collected from medical files. Preoperative radiographs of the affected knees were compared with those of the unaffected knees using the score system described by Larsen et al. Operative data and postoperative course were reviewed.

The diagnosis of rheumatoid nodule was based on history and physical examination and was confirmed by histological examination of the excised lumps. Central fibrinoid necrosis surrounded by palisading histiocytic cells was considered diagnostic of rheumatoid nodules (figs 1 and 2).

Results
Six women and one man were identified with symptoms during walking caused by intra-articular rheumatoid nodules. All patients had seropositive rheumatoid arthritis. The mean disease duration was 11.9 years (range 3–33 years, SD=10.7). The mean age of the patients was 53 years (range 39–69 years).

All patients had a history of recurrent pain accompanied by clicking, locking, and giving way of the affected knee joint. In three patients this triggering of the knee joint occasionally caused stumbling and falling. It was noted in one patient that in the presence of a gross joint effusion the triggering and pain disappeared. It recurred soon after removal of the synovial fluid, or after the administration of an intra-articular injection of corticosteroids.
On physical examination a moderate synovitis with slight effusion was found in four patients and a firm lump was palpable in all seven. The lump appeared to be attached to the capsule. In six patients the lump was situated on the lateral side and in one patient on the medial side of the patella. On flexing the knee, the lump slipped over the underlying tibial plateau and hid behind the patella. Sometimes it was caught on the tibial plateau and caused triggering of the knee joint. This could be perceived as a palpable 'click'. Anteroposterior and lateral radiographs did not show abnormalities that could account for the presence of intra-articular rheumatoid nodules. Only slight narrowing of the joint space was seen in five patients (Larsen score 0–1). Erosions were absent. In two patients the radiographs were normal. Affected and unaffected knees could not be distinguished radiologically.

All the lumps were excised within two years after the first symptoms. Their dimensions varied from $1 \times 1 \times 1$ cm to $3 \times 2.5 \times 1.5$ cm. The localisation appeared to be intracapsular—that is, within the fibrous capsule of the knee joint.

In six of the seven patients the diagnosis of rheumatoid nodule was confirmed by histological findings. In one patient insufficient material was obtained for histological examination. The synovium showed a mild inflammatory reaction in all patients.

The postoperative course was uneventful in all but one patient. In this patient haemarthrosis developed within two weeks during anti-coagulant prophylaxis. In all patients triggering of the knee disappeared after removal of the rheumatoid nodules. Two patients had a symptomatic recurrence of the rheumatoid nodule within one and two years. Two to seven years after excision the others were still asymptomatic.

**Discussion**

Walking problems are a common clinical symptom in patients with rheumatoid arthritis. Usually they are due to arthritis, instability of the lower limb joints, or loss of muscle strength. Rare causes of walking problems in rheumatoid arthritis include normal pressure hydrocephalus and myelopathy.

We report here intra-articular rheumatoid nodules of the knee joint as another cause of walking problems in patients with seropositive rheumatoid arthritis. Entrapment of an intra-articular rheumatoid nodule on the ridge of the tibial plateau has an easily recognisable clinical pattern consisting of clicking, locking, and giving way of the knee joint. This clinical pattern is comparable with trigger finger or trigger wrist. Thus 'trigger knee' seems to be the most suitable name for this phenomenon.

Chamberlain reported another clinical feature of intra-articular rheumatoid nodules, namely the lack of full extension of the knee, resulting in walking problems. In three of our patients triggering of the knee joint resulted in stumbling and falling. To our knowledge, such severe walking problems have not yet been reported in association with intra-articular rheumatoid nodules. The differential diagnosis of triggering of the knee joint also includes intra-articular loose bodies, meniscal tears and cysts, ganglions, and patellar osteophytes.

In our patients the presumed diagnosis of intra-articular rheumatoid nodules of the knee joint was easily made solely by history and physical examination. Ultrasonography is possibly useful in distinguishing intra-articular rheumatoid nodules in several joints. As a result of the localisation of the rheumatoid nodules within the fibrosis capsule, we conclude that arthroscopy will be superfluous in most patients with intra-articular rheumatoid nodules of the knee joint.

In our series of patients anteroposterior and lateral radiographs of the affected knees showed surprisingly little damage and had a similar Larsen score to those of the unaffected knees, as shown by other workers.

In conclusion, intra-articular rheumatoid nodules can cause serious walking problems in patients with seropositive rheumatoid arthritis due to triggering of the knee joint, as a result of entrapment of the nodule on the ridge of the tibial plateau. This phenomenon is probably rare: only seven patients with trigger knee caused by intra-articular rheumatoid nodules were identified during 17 years in our rheumatology outpatient clinic. As most of the intra-articular rheumatoid nodules will probably remain symptomless, it is difficult to predict how often they really occur. In accordance with the other workers, most of the nodules were located on the lateral side of the patella (86% of patients) and only one (14%) medially. The diagnosis can easily be made on the basis of the typical clinical manifestations and confirmed by histological examination. No additional investigations are required. Complete relief of the symptoms can be obtained by excision of the nodule.

The authors thank Dr J D Macfarlane for revising the English text.

Intra-articular rheumatoid nodules and triggering of the knee joint


Treatment of resistant giant cell arthritis with etanercept

Tan et al recently described a case of “resistant giant cell arthritis” successfully treated with etanercept.1 Their patient, who had classical symptoms of polymyalgia rheumatica (PMR), developed headaches while receiving low dose steroids. Biopsy of a temporal artery showed no arteritis. Because giant cell arthritis (GCA) was suspected on clinical grounds, high dose steroids were instituted. Six months later, despite continued steroid treatment, a transient ischaemic attack (TIA) involving right arm weakness occurred, which was ascribed to “arteritis (sic)”. An insufficiency fracture ensued. As the erythrocyte sedimentation rate and C (sic) ‘’normalised, and was made, and etanercept was given. The acute phase reactants normalised, and the symptoms referable to PMR resolved completely.

I am not persuaded that the patient in question had GCA.

Firstly, the temporal artery biopsy was negative. Definitive criteria for the entity of so-called biopsy negative GCA are lacking, and, in my opinion, this concept remains a problematic one. Negative temporal artery (TA) biopsies do occur in certain subsets of GCA—for example, upwards of 50% of patients with so-called large artery involve- ment have such negative biopsies—but the extent to which TA biopsies are negative in bona fide cases of cranial arteritis in GCA is unclear. Two recent papers have suggested that reported rates of TA biopsy negative for arteritis markedly reduces the probability of the diagnosis of GCA, because the yield of a positive contralateral biopsy is no more than 1–3%.

The issue of what constitutes a flare in GCA (and PMR) is also problematic. It has been my experience over the years that many cases of alleged flares of both conditions involve little more than asymptomatic rises in the acute phase reactants, and that the pursuit of such rises with increased doses of steroids not uncommonly results in sundry untoward complications—notably, steroid induced osteoporosis and associated frac- tures.

The patient under discussion is a case in point. The acute phase reactants were raised coincident with the occurrence of a TIA, but it is unlikely that this latter episode was caused by GCA. Though GCA is occasionally compli- cated by stroke, such an event nearly always involves the territory of the vertebro-basilar circulation, and rarely occurs in the distribution of the internal carotid artery. The explanation for this fact may result from the specific exclusion of the intracranial arteries from involvement by GCA, possibly because these arteries lack an internal elastic lamina, which plays a pivotal role in the pathogenesis of GCA. The internal elastic lamina is said to be maintained for a few millimetres after the vertebral arteries pierce the dura, thus accounting for the strokes referable to the vertebral-basilar circulation.1 The patient described by Tan et al had left arm weakness, almost surely attributable to ischaemia of the middle cerebral artery, thus effectively ruling out GCA as the cause for the TIA.

I therefore submit that this patient did not have “resistant giant cell arteritis”; rather, he represents a case of the successful treatment by tumour necrosis factor α (TNFα) blockade of symptoms and signs referable to PMR.

One final caveat: although further study may show that TNFα blockade does successfully reduce the levels of cytokines that drive the acute phase response in GCA, thus ameliorating constitutional symptoms and signs, this treatment may not mitigate the disease’s most feared consequence—namely, ischaemia leading to visual loss. As demon- strated by elegant work over the past decade by Weyands and Goronzy,11 ischaemia in GCA results from an array of other cytokines with pathogenic potential—for example, platelet derived growth factor and vascular endothelial growth factor, which would be unaffected by TNFα’s blockade.

W P Docken
Brigham and Women’s Hospital, Boston, MA 02115, USA

Correspondence to: Dr W P Docken, 850 Boylston St, Chestnut Hill, MA 02467, USA; wbdocken@partners.org

References


Authors’ reply

We thank Dr Dockens for his comments on the difficulty in the diagnosis, treatment, and classification of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, the sole purpose of our case report was to show how etanercept might have a role in the treatment of resistant disease of the PMR/GCA spectrum. From a clinical standpoint we are happy to label our patient a “resistant giant cell arteritis” because these arteries lack an internal elastic lamina, thus accounting for the strokes referable to the vertebral-basilar circulation.1 The patient described by Tan et al had left arm weakness, almost surely attributable to ischaemia of the middle cerebral artery, thus effectively ruling out GCA as the cause for the TIA.

We therefore submit that this patient did not have “resistant giant cell arteritis”; rather, he represents a case of the successful treatment by tumour necrosis factor α (TNFα) blockade of symptoms and signs referable to PMR.

One final caveat: although further study may show that TNFα blockade does successfully reduce the levels of cytokines that drive the acute phase response in GCA, thus ameliorating constitutional symptoms and signs, this treatment may not mitigate the disease’s most feared consequence—namely, ischaemia leading to visual loss. As demonstrated by elegant work over the past decade by Weyands and Goronzy11, ischaemia in GCA results from an array of other cytokines with pathogenic potential—for example, platelet derived growth factor and vascular endothelial growth factor, which would be unaffected by TNFα’s blockade.

W P Docken
Brigham and Women’s Hospital, Boston, MA 02115, USA

Correspondence to: Dr W P Docken, 850 Boylston St, Chestnut Hill, MA 02467, USA; wbdocken@partners.org

Fenofibrate and losartan

The leader by Professor Bardin1 makes an excellent point. We could benefit from the hypouricaemic action of drugs that are not licensed for this use (for example, losartan and fenofibrate).

Other drugs in common use may also have a uricosuric effect. For example, atorvastatin can reduce serum uric acid concentrations in patients with peripheral arterial disease or hyperlipidaemia.4 However, the mechanisms involved are not clear cut; we speculate that atorvastatin can increase renal blood flow and decrease serum creatinine levels.5 Thus, the Medical Research Council/British Heart Foundation Heart Protection Study (HPS) showed that simvastatin decreased the deterioration of the glomerular filtration rate (GFR) over a period of 4.6 years in high risk patients with (n = 5963) or without (n = 14 573) diabetes.6 This effect on GFR would almost certainly influence urate excretion. These statin mediated effects are relevant because, as Professor Bardin points out, patients with hyperuricaemia may also be dyslipidaemic.

Closer to the interests of rheumatologists are the non-steroidal anti-inflammatory drugs (NSAIDs). Some NSAIDs may exert a favourable effect on urate excretion. For example, diflunisal has been reported to have a uricosuric effect, although the inhibition of xanthine oxidase activity has also been proposed.7 Azapropazone (not used as a first-line option) has been shown to lower serum urate levels.8 Indomethacin may have uricosuric properties.7 Tiaprofenic acid
NOTIFICATION AND CORRECTION

Corrections printed in the journal also appear on the Annals website
www.annrheumdis.com
and are linked to the original publication

NOTICE


The name of the first author of this paper has changed from Tak-Diamant Z to Diamant Z.


doi: 10.1136/ard.2002.005371er01

We regret that the references for this letter were omitted. They are given below.


INTERNATIONAL CONGRESS ON SLE AND RELATED CONDITIONS

9–13 May 2004; New York, New York, USA

Contact: The Oakley Group, 2014 Broadway, Suite 250, Nashville, Tennessee 37203, USA
Tel: +1 615 322 2785
Fax: +1 615 322 2784
Email: Lupus2004@theoakleygroup.com
Website: http://www.lupus2004.org

IOF WORLD CONGRESS ON OSTEOPOROSIS

14–18 May 2004; Rio de Janeiro, Brazil

IOF awards are available for scientists: IOF Claus Christiansen Research Fellowship: 45 000
IOF Servier Young Investigator Fellowship: 40 000
Contact: Congress Secretariat at info@osteofound.org
Website: www.osteofound.org

INTERNATIONAL SOCIETY FOR THE STUDY OF THE LUMBAR SPINE

31 May–5 June 2004; Porto, Portugal

Contact: International Society for the Study of the Lumbar Spine, 2075 Bayview Avenue, Room MG 323, Toronto, Ontario, Canada M4N 3M5
Tel: 00 1 416 480 4833
Fax: 00 1 416 480 6055
Email: shirley.fitzgerald@sw.ca

8th EULAR Sonography Course

7–9 June 2004; Berlin, Germany

Organising Committee: Marina Backhaus, Wolfgang Schmidt
Contact: Congress Organisation: Gedel Congress Service
Tel: +49-30-22488390
Fax: +49-30-22488389
Email: gedel.cm@t-online.de
Website: www.eular.org

First European Course: Capillaroscopy and Rheumatic Diseases

10–12 September 2004; Genova, Italy
Contact: Scientific Secretariat: Professor Maurizio Cutolo, Division of Rheumatology, DIMI, University of Genova, Italy
Email: mcutolo@unige.it
Organising Secretariat: Michela Civelli, EDRA spa, Viale Monza , 133 – 20125, Milan, Italy
Fax: +39 02 281 72300
Email: eulaccongress@dsmedigroup.com

Xth International Conference on Behçet’s Disease

27–31 October 2004; Antalya, Turkey
Contact: Congress Secretariat, Figur Congress and Organization Services Ltd. STL, Ayazmaderesi Cad. Karadut Sok. No: 7 80888 Dikilitas, Istanbul, Turkey
Tel: +90 (0212) 258 6020
Fax: +90 (0212) 258 6078
Email: behcet2004@figur.net
Website: www.behcet2004.org

www.annrheumdis.com